Promoter-proximal pausing of RNA polymerase II (Pol II) is a major checkpoint in transcription. An unbiased search for new human proteins that could regulate paused Pol II at the HSPA1B gene identified TRIM28. In vitro analyses indicated HSF1dependent attenuation of Pol II pausing upon TRIM28 depletion, whereas in vivo data revealed de novo expression of HSPA1B and other known genes regulated by paused Pol II upon TRIM28 knockdown. These results were supported by genome-wide ChIP-sequencing analyses of Pol II occupancy that revealed a global role for TRIM28 in regulating Pol II pausing and pause release. Furthermore, in vivo and in vitro mechanistic studies suggest that transcription-coupled phosphorylation regulates Pol II pause release by TRIM28. Collectively, our findings identify TRIM28 as a new factor that modulates Pol II pausing and transcriptional elongation at a large number of mammalian genes. npg
a r t i c l e s Promoter-proximal pausing of Pol II represents a major checkpoint in transcription. Typically, Pol II enzymes pause at around nucleotides +30-100 relative to the transcriptional start site (TSS) until activating cellular signals induce elongation 1 . Although promoter-proximal pausing was discovered over two decades ago, it was initially thought to occur at only a limited set of genes 2 . Recently, however, genomewide analyses such as chromatin immunoprecipitation followed by sequencing (ChIP-seq) and global run-on sequencing have shown that promoter-proximal pausing is widespread 1, [3] [4] [5] [6] [7] . For instance, approximately 30% of coding genes and over 70% of developmental or inducible genes exhibit Pol II paused at promoter-proximal sites 8, 9 . Thus, promoter-proximal pausing is considered a major cellular mechanism to regulate gene expression.
Although the mechanisms of Pol II pausing and pause release are incompletely understood, several transcription factors are known to regulate these processes. DSIF and NELF induce and stabilize pausing 10 , whereas TFIIS 3 , Myc and P-TEFb help release Pol II from the pausing site 1 . P-TEFb phosphorylates DSIF, NELF and the C-terminal domain of Pol II (Pol II CTD), and phosphorylation of these factors correlates with pause release 11 . The eukaryotic genes encoding Hsp70 (here denoted Hsp70) are an appropriate model for the study of promoter-proximal pausing. Especially in Drosophila, Pol II pausing has been extensively studied at Hsp70: Pol II pausing occurs around +30 (ref. 12) relative to the TSS, and factors such as NELF and DSIF 10 regulate pausing. However, less is known regarding pausing at human genes including HSP70. Although the fundamental mechanisms of promoter-proximal pausing might be evolutionarily conserved, the degree of conservation is uncertain. For example, HSF1, a master HSP70 activator, is conserved in the DNA-binding and trimerization domains but differs in its regulatory and activation domains between Drosophila and humans 13 . Knockdown (KD) of Spt5 (a subunit of DSIF) largely controls pausing, but NelfA KD is less effective in mouse embryonic stem (mES) cells 1 , and NELF KD unexpectedly decreases Pol II density at NELF-regulated genes in humans 14 . NELF is less conserved in eukaryotes and is lacking in Caenorhabditis elegans and Saccharomyces cerevisiae. In addition, elongation factors such as Gdown1 (ref. 15 ) and ELL 16 have been reported to regulate Pol II promoter-proximal pausing in humans, yet orthologs for these factors are unknown in Drosophila. These observations imply diversity and complexity of Pol II promoterproximal pause-regulatory mechanisms in mammals.
To further probe the factors and mechanisms that regulate Pol II pausing, we initiated an unbiased approach to screen for factors that could selectively bind the nontemplate strand of the well-studied human HSPA1B (also known as HSP70-2) gene. These experiments were based upon the concept of nucleic acid aptamers, short singlestranded nucleic acid polymers that can bind protein factors with high affinity and selectivity 17 . We reasoned that, for a paused Pol II enzyme, a nontemplate single-stranded DNA of about 20 bases around the transcription bubble could be available for protein factors to bind. Genes regulated by paused Pol II typically contain GC-rich sequences, such as GAGA motifs or the pause-button motif, at their promoters 18, 19 . The high GC content at the TSS of HSPA1B could facilitate formation of secondary structures that might form a binding motif for a specific protein factor ( Supplementary Fig. 1a ).
Using single-stranded DNA (ssDNA) oligonucleotide-protein binding assays and MS, we identified the TRIM28 protein as a factor that bound specifically and selectively to the nontemplate strand of the HSPA1B promoter. TRIM28 is a multidomain transcriptional regulator linked to activation and repression of a subset of genes 20 . Its abnormal expression is implicated in disorders related to cell growth 21 , development 22 and differentiation 23, 24 . To understand the function of TRIM28 bound at the promoter-proximal pausing site, we performed in vitro transcription assays and in vivo KD experiments. Genome-wide ChIP-seq analyses of Pol II comparing wild-type (WT) and TRIM28-KD mES cells suggest a global function of TRIM28 in controlling Pol II pause release. In addition, we identified a rapid phosphorylation event in TRIM28 upon HSPA1B activation in vivo. We thus propose that a new pausing factor, TRIM28, regulates Pol II promoter-proximal pausing and progression into processive elongation at a large number of genes in mammals, and regulation of its activity involves post-translational modification.
RESULTS

TRIM28 binds to the HSPA1B promoter-proximal pausing site
First, using protein pulldown with the immobilized HSPA1B ssDNA nontemplate strand and subsequent MS, we screened for potential unidentified pausing factors. Considering the structural flexibility of nontemplate ssDNA and its likely accessibility outside the Pol II cleft 25 , we hypothesized that nontemplate DNA might be recognized by proteins that regulate pausing. We subjected the nontemplate ssDNA oligonucleotides of HSPA1B +1-50 and +1-80 regions, along with +1-50 of GREB1 (used as a nonpausing control gene) 26 to pulldown assays with HeLa NE (Supplementary Fig. 1a ). We applied stringent wash conditions to screen proteins bound to each oligonucleotide with high affinity and identified only a few proteins with high confidence through such wash conditions by MS ( Fig. 1a , Table 1 and Supplementary Fig. 1b ). TRIM28 was associated with the +1-80 HSPA1B sequence but not with the +1-50 sequences of HSPA1B or GREB1 ( Table 1 and Fig. 1b ). Immunoblotting confirmed that TRIM28 specifically bound to the +1-80 sequence but not to +1-50 of HSPA1B or GREB1 (Fig. 1b) . These results suggested that TRIM28 binds to the nontemplate DNA of HSPA1B, in particular to the segment between +50 and +80. Although TRIM28 is not known as a ssDNA-binding protein (for example, unlike PURb, Fig. 1b) , we identified TRIM28-binding motifs, GCCGCG (ref. 23) , at +60-65 and +62-67 of the HSPA1B promoter, both with an 83% homology to consensus (Fig. 1c) . These data prompted further examination to determine whether TRIM28 might function in Pol II promoterproximal pause regulation.
Pol II pausing at human HSPA1B in vitro
We immobilized a biotinylated fragment of the native human HSPA1B gene (−467 to +216) on streptavidin beads and used this template to assess transcription in vitro with HeLa nuclear extract (NE) ( Fig. 1d,e and Supplementary Fig. 2b ). Importantly, our transcription system visualized all species of de novo transcripts, enabling us to monitor transcription activities ranging from abortive initiation to processive elongation. Through this method, we visualized a Pol II pausing site on human HSPA1B. Upon titrating NE, we observed a stable and prominent RNA transcript at around +70 without detectable runoff or extended transcripts, thus suggesting a native tendency of the HSPA1B template for Pol II pausing ( Fig. 1f) . We also noted that Pol II pausing occurred near the TRIM28-binding motif (Fig. 1c) . These data suggested that our in vitro system could accurately recapitulate a r t i c l e s npg a r t i c l e s stable Pol II pausing at the HSPA1B promoter, with stable pausing occurring at around +70, near the TRIM28-binding site.
TRIM28 attenuates HSF1-mediated pause release in vitro
We hypothesized that TRIM28 might repress HSPA1B transcription by augmenting promoter-proximal pausing. To assess this possibility, we performed transcription assays ( Fig. 1e ) using TRIM28-immunodepleted HeLa NE (TRIM28∆NE) ( Fig. 2a and Supplementary Fig. 2e ). TRIM28∆NE displayed transcription potential comparable to that of WT NE ( Fig. 2b) , thus indicating that TRIM28 depletion does not affect the general transcription efficiency at the HSPA1B promoter under these conditions. In vivo, HSF1 is rapidly recruited to HSP70 promoters upon heat shock to activate transcription 27 . In our immobilized-template assays, HSF1 enhanced recruitment of preinitiation complex (PIC) factors and P-TEFb proteins to the HSPA1B template DNA (Fig. 2c) . Therefore, we included HSF1 to recapitulate HSPA1B activation in vitro. We assembled native PIC and naturally associating proteins on the template with NE and removed proteins unbound or bound loosely by washing with transcription buffer. Then we added NTPs, including radioactively labeled CTP, to initiate transcription and to allow visualization of nascent RNA products ( Fig. 1e) .
We introduced HSF1 to the transcription reaction at different time points in order to stimulate HSPA1B at distinct transcriptional stages: t0 during PIC formation; t1 immediately after PIC formation; and t2 after Pol II paused at the promoter-proximal site (Fig. 1e) . Pol II pausing was evident in the absence of HSF1 in both WT and TRIM28∆NE with little evidence of runoff transcripts (Fig. 2d) . This suggested that Pol II pausing occurred in uninduced HSPA1B with or without TRIM28. When HSF1 was added at t0, transcription was stimulated in both WT and TRIM28∆NEs (Fig. 2d) , perhaps owing to enhanced recruitment of PIC proteins by HSF1 ( Fig. 2c) . Importantly, pausing was dramatically diminished in TRIM28∆NE, but not in WT NE, when we introduced HSF1 to the established PIC (t1) or to the paused complex (t2; Fig. 2e ). Thus, HSF1 added at t1 and t2 appeared to release paused Pol II more effectively in the absence of TRIM28. Addition of HSF1 at t1 (after PIC assembly) or t2 (after formation of paused Pol II) mimics HSF1-mediated HSPA1B activation in vivo, in which Pol II has assembled into the PIC or has paused near the promoter. Because paused transcripts (+70) were diminished and runoff transcript levels were increased in TRIM28∆NE, these results suggested that TRIM28 could be functioning to stabilize paused Pol II in the presence of HSF1.
To verify that other proteins immunodepleted along with TRIM28 were not contributing to the difference in TRIM28∆NE activity, we identified proteins bound to the anti-TRIM28 antibody by MS ( Fig. 2f and Supplementary Data Sets 1 and 2). On the basis of their known 25 15 TRIM28 (141), HSPA8 (9) HSPA5 (8), IQGAP1 (7) HSPA9 (7) , IPO8 (6), NUP155 (2) TRIM28 (16), ANXA2 (13) GAPDH (6), CAPZA1 (7) COPS4 (3), ALDOA (2), ZNF483 (2) CBX3 (5) npg a r t i c l e s functions, the proteins that coimmunoprecipitated appeared unlikely to function in promoter-proximal pausing. More importantly, purified TRIM28 resupplied to TRIM28∆NE in the transcription assay restored Pol II pausing, thus validating that TRIM28 was indeed responsible for the formation of stably paused Pol II complexes ( Fig. 2g and Supplementary Fig. 2c ).
TRIM28 controls expression of known paused genes in vivo
Because TRIM28 was shown to affect HSPA1B transcription in vitro, we next examined whether TRIM28 KD would alter expression of HSPA1B in cells. Because TRIM28 depletion facilitated Pol II pause release in vitro, we hypothesized that Pol II pausing may become attenuated in TRIM28 KD cells and may increase the basal levels of HSPA1B mRNA expression in vivo. Using two short hairpin RNA (shRNA) species targeting TRIM28 (KD1 and KD2), we knocked down the factor in HEK293 cells. The mRNA and protein levels of HSPA1B, measured by quantitative PCR (qPCR) and immunoblotting, were increased in TRIM28 KD cells but not in controls with scrambled shRNA species (Fig. 3a) . Therefore, as expected, Pol II pausing appeared to be attenuated in TRIM28 KD cells, thus permitting Pol II progression from the pause site into the open reading frame of HSPA1B.
Recently, it has been reported that genes in immune-responsive and signal-transduction pathways can be highly paused 28 . Because TRIM28 is known to regulate immune responses and cell proliferation 21, 24 , we examined NFκB (RELA) and ERK1 (MAPK3). These genes broadly regulate immune response and proliferation and have been previously shown to have paused Pol II at their promoters 28 . Consistently with this, CDK9 KD reduced the expression of HSPA1B, NFκB and ERK1, thus suggesting that these genes are dependent on P-TEFb and are regulated by Pol II pausing in HEK293 cells (Fig. 3b) . We also noted that NFκB and ERK1 possess TRIM28-binding motifs within their promoter regions (+47-52 for ERK1 and +7-12 for NFκB with 100% consensus). Immunoblotting and qPCR indicated upregulation of NFκB and ERK1 in TRIM28 KD cells (Fig. 3c) .
TRIM28 regulates Pol II pausing genome wide
Existing ChIP-microarray (ChIP-chip) data have indicated that TRIM28 is frequently located near the TSSs of many protein-coding genes 23 . From our cellular, biochemical and in vitro data, we hypothesized that TRIM28 may function in Pol II promoter-proximal pausing genome wide. Therefore, we performed ChIP-seq to investigate the global impact of TRIM28 on Pol II occupancy. Given the overall coding conservation between mice and humans 29 , mES cells provided a useful model system for this investigation. Specifically, the pausing genes evaluated in this study such as EGR1, JUN, ERK1 and HSPA1B are highly conserved between humans and mice, with over 92% coding similarity.
We defined TSS and TTS-proximal windows as start or end ±250, respectively, and defined gene-body windows as +500-2500; if the size of a gene was smaller than 2,500 bp, the gene-body window was defined as +500 to the gene end. After TRIM28 KD by short interfering RNA (siRNA) in mES cells (Fig. 4a) , the pausing index (Pol II TSS occupancy/gene-body occupancy) was either increased or decreased by over two-fold at 41.3% of mappable protein-coding genes, as compared to WT. As expected, the pausing index of established paused genes such as Jun and Egr1 was decreased in TRIM28 KD (Fig. 4b) .
The pausing index of Hspa1b and Erk1 was decreased consistently with the in vivo KD and gene-expression results ( Figs. 3 and 4b) .
We also report a series of genes in different signaling pathways whose pausing index was notably altered by TRIM28 KD ( Table 2) . In agreement with our results, a metagene analysis based on previous TRIM28 ChIP-chip data 23 indicated that TRIM28-bound genes increased the mean gene-body Pol II occupancy upon TRIM28 KD ( Fig. 4c and Supplementary Fig. 3a,b) . Importantly, TRIM28 KD led to elevation of Pol II occupancy within the gene body (between +250 and +999 from the TSS) at a number of coding genes ( Fig. 4d and Supplementary Figs. 3c-e, 4 and 5 ). TRIM28 KD also increased occupancy of S2-phosphorylated Pol II within the gene body, between +250 and +999 from the TSS, as shown by metagene analysis of 15,917 coding genes (Fig. 4e) . Chromosome views of individual loci (Ier5 and DQ072391) further illustrate a role for TRIM28 in Pol II progression ( Fig. 4f and Supplementary Fig. 6) . At Ier5, Pol II occupancy increases downstream of the TSS and in the gene body as assessed by total Pol II and S2-phosphorylated Pol II upon TRIM28 KD (Fig. 4f) .
Overall, these results support a new function for TRIM28 in regulating Pol II promoter-proximal pausing and pause release.
Rapid phosphorylation of TRIM28 upon HSPA1B activation
We next attempted to identify mechanisms through which TRIM28 inhibition of Pol II pause release might be regulated. We initially asked whether TRIM28 was released from the HSPA1B promoter upon activation of HSPA1B transcription. Thus, we heat-shocked HEK293 cells over a time course of 0, 0.5, 2 and 5 min and monitored TRIM28 occupancy at HSPA1B by ChIP followed by qPCR with primer sets to amplify the HSPA1B promoter and TSS (Fig. 5a) . As reported for Drosophila Hsp70 (ref. 27) , HSF1 was rapidly recruited to the HSPA1B promoter within 30 s of heat shock (Fig. 5b) . Notably, TRIM28 did not dissociate from the TSS of HSPA1B at these time points (Fig. 5c) .
TRIM28 has been reported to be phosphorylated at S824 under specific circumstances, and this has been associated with chromatin structural changes [30] [31] [32] . In addition, a study showed that TRIM28 was phosphorylated at S824 when p21 (CDKN1A), a TRIM28regulated gene, was transcriptionally activated 33 . Therefore, we inspected TRIM28 S824 phosphorylation at HSPA1B upon heatshock induction. We induced HSPA1B expression in HEK293 cells by heat shock over a time course of 0, 0.5, 2 and 5 min and quantified occupancy of S824-phosphorylated TRIM28 at HSPA1B with ChIP followed by qPCR. TRIM28 became rapidly phosphorylated at S824, an effect apparent within 30 s of heat shock, and the phosphorylated TRIM28 dramatically increased in an activating signal-dependent manner (Fig. 5d) .
To search for the kinase that phosphorylates TRIM28 at S824, we used immunoprecipitation followed by MS. Because protein kinases were not among the few proteins that coimmunoprecipitated with TRIM28 under stringent wash conditions, we initiated a set of TRIM28 immunoprecipitation experiments that used less-stringent washes followed by medium-salt elution (Supplementary Fig. 7b ). Through this method, we identified DNA-dependent protein kinase (DNA-PK) by MS to coimmunoprecipitate with TRIM28 (list of identified proteins in Supplementary Data Set 3) . In addition, ataxia telangiectasia mutated (ATM), another member of the phosphoinositide 3-kinase family, is known to phosphorylate TRIM28 at S824 in the DNArepair process 32, 33 . Therefore, we investigated whether DNA-PK or ATM were required for TRIM28 phosphorylation at S824 during HSPA1B activation by using specific inhibitors for each kinase, NU7441 (ref. 34 ) and KU55933 (ref. 34 ). In addition, we included an HSF1 inhibitor, npg a r t i c l e s KRIBB11 (ref. 35) , which allows HSF binding to the promoter but interferes with HSF-mediated P-TEFb recruitment, to test whether HSF1-P-TEFb interaction was responsible for TRIM28 phosphorylation at S824. We added each kinase inhibitor (NU7441, 2 µM; KU55933, 10 µM; and KRIBB11, 10 µM, in 0.1% DMSO as a final concentration) to HEK293 cells 1 h before 5-min heat shock (or no heat shock for controls).
The results showed that both DNA-PK and ATM inhibitors effectively reduced heat shock-induced TRIM28 S824 phosphorylation at the TSS of HSPA1B upon heat shock (Fig. 5e) . By contrast, the HSF1-P-TEFb inhibitor KRIBB11 did not affect this phosphorylation, thus suggesting that TRIM28 S824 phosphorylation is not mediated by P-TEFb.
We measured Pol II occupancy at the TSS and a distal site of HSPA1B, under similar experimental conditions. Total Pol II occupancy at the TSS increased with or without each of the inhibitors upon heat shock (Fig. 5e) , a result implying that these inhibitors did not markedly influence Pol II recruitment to the TSS upon activation. Importantly, DNA-PK and ATM inhibitors abolished the increase of Pol II occupancy at the 3′ end of HSPA1B upon heat shock, contrasting with DMSO controls, thus implying reduced Pol II elongation (Fig. 5e) . The inhibitor of the HSF1-P-TEFb interaction, KRIBB11, also reduced Pol II occupancy at the 3′ end of HSPA1B, probably owing to reduced P-TEFb recruitment. Thus TRIM28 S824 phosphorylation appeared to be regulated by DNA-PK and ATM and correlated with Pol II progression toward the 3′ end and transcriptional elongation at HSPA1B.
Because a post-translational modification at the C-terminal domain of TRIM28 was involved in the release of its repressive function, we tested a C-terminal-deletion mutant of TRIM28 (residues 1-617, TRIM28∆CTD; Supplementary Fig. 2c ) for its effect on Pol II promoter-proximal pausing in vitro. When we titrated TRIM28∆CTD to TRIM28∆NE, Pol II pausing increased in a dose-dependent manner upon HSF1 induction (Fig. 5f) . This suggested that TRIM28∆CTD could stabilize Pol II pausing.
To further test whether TRIM28 phosphorylation at S824 was critical to regulate Pol II pausing, we compared TRIM28 S824A and S824D mutants with WT TRIM28 in the in vitro transcription assay. We supplemented purified TRIM28 (WT, S824A or S824D) with WT or TRIM28∆NE during PIC formation on HSPA1B template DNA (Supplementary Fig. 7a,c) and found that WT TRIM28 and the S824A mutant augmented Pol II pausing (Fig. 5g,h and Supplementary Fig. 8 ). Bottom, a gene-activating signal modulates TRIM28 to suppress its repressive function, and Pol II is released from the pausing site into the gene body. At HSPA1B, TRIM28 remains at the TSS but is phosphorylated at S824 by DNA-PK and ATM upon heat shock. This post-translational modification correlates with Pol II pause release at HSPA1B. npg a r t i c l e s By contrast, the TRIM28 S824D mutation (which mimics phosphorylation) destabilizes Pol II pausing in vitro. Together with the in vivo data (Fig. 5d,e) , these results implicate TRIM28 S824 phosphorylation as a means to regulate Pol II pausing at HSPA1B. In particular, these data suggest that nonphosphorylated TRIM28 at S824 functions in stabilizing Pol II pausing, whereas S824-phosphorylated TRIM28 facilitates Pol II pause release at HSPA1B.
DISCUSSION
Using an unbiased approach, we have identified TRIM28 as a new pausing factor that binds to the nontemplate DNA near the Pol II pausing site of HSPA1B. Our results suggest that TRIM28 can stabilize paused Pol II and that TRIM28 helps regulate release of paused Pol II complexes. TRIM28 depletion in vitro facilitated Pol II pause release by HSF1 (Fig. 5i) . In vivo, TRIM28 contributes to Pol II promoter-proximal pausing genome wide, on the basis of experiments that showed increased Pol II occupancy downstream from the TSS (>+250) at a wide spectrum of genes after TRIM28 KD. In addition, we have shown that TRIM28 was phosphorylated at S824 upon HSPA1B activation, in a manner dependent on DNA-PK and ATM. Our in vivo and in vitro data suggest that TRIM28 phosphorylation at S824 regulates Pol II pause release.
TRIM28 has been shown to be a powerful suppressor of transcription through the formation of complexes with ZNFs and HP1 proteins 36 , and TRIM28 interacts with the repressive NuRD complex and SETDB1 (ref. 37) . Previous studies have shown that TRIM28 phosphorylation at S824 can promote chromatin relaxation 30, 32 ; similar chromatin-based changes could facilitate Pol II release from the pausing site of HSPA1B. It will be of future interest to determine whether this phosphorylation event regulates TRIM28 interaction with histone modifiers such as SETDB1 and the NuRD complex at HSPA1B. Notably, TRIM28 interaction with SETDB1 and the NuRD complex requires SUMOylation on TRIM28, and this modification is inhibited by phosphorylation of TRIM28 at S824 (refs. 33, 37) . Furthermore, nucleosome occupancy is enriched at many genes immediately downstream of the Pol II pausing site at the +1 nucleosome 38 , and TRIM28 may thus function in stabilizing paused Pol II through interaction with such structures.
Our observation that TRIM28 regulates Pol II pausing and pause release at a broad array of protein-coding genes suggests that diverse regulatory mechanisms and signaling pathways might converge upon TRIM28 to regulate Pol II activity. TRIM28 is known to localize at the TSSs of genes that regulate the cell cycle and growth, and deregulation of TRIM28 expression is closely linked to the development of different cancers 23, 39 . Consistently with this, our Pol II ChIP-seq data indicated that TRIM28 KD alters the pausing index of genes involved in cell growth and apoptotic pathways. It is plausible that disruption of TRIM28 function or expression deregulates expression of key growth or tumor-suppressor genes by altering the activity of paused Pol II complexes. Thus, TRIM28 and the signaling pathways that control its phosphorylation state may provide a means to selectively control this key regulatory checkpoint, and this could ultimately yield new therapeutic approaches for a subset of cancers.
METHODS
Methods and any associated references are available in the online version of the paper.
Accession codes. ChIP-seq genomic data described in this study have been deposited in the Gene Expression Omnibus database under accession number GSE48253. npg a r t i c l e s
